OVERVIEW OF PRE-CLINICAL TECHNIQUES FOR PREDICTING THE IMMUNOGENICITY OF THERAPEUTICS IN DRUG DEVELOPEMENT Por Clarisse Musanabaganwa, Fidele Byiringiro

Assuntos: “...immunogenicity...”
Obter o texto integral

Adjuvants in vaccines registered for human use Por Filipić Brankica, Stojić-Vukanić Zorica

Assuntos: Obter o texto integral

Current Biosafety Considerations in Stem Cell Therapy Por Masoumeh Mousavinejad, Peter W. Andrews, Elham Kargar Shoraki

Assuntos: Obter o texto integral

A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area Por Jemal Hussein, Martha Zewdie, Lawrence Yamuah, Ahmed Bedru, Markos Abebe, Alemnew F. Dagnew, Menberework Chanyalew, Asfawesen G. Yohannes, Jemal Ahmed, Howard Engers, T. Mark Doherty, Peter Bang, Ingrid Kromann, Søren T. Hoff, Abraham Aseffa

Assuntos: Obter o texto integral

Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response against Trypanosoma cruzi, characterized by an increased level of polyfunctional CD8+ T-ce... Por Cristina Poveda, Ana Carolina Leão, Chiara Mancino, Francesca Taraballi, Yi-Lin Chen, Rakesh Adhikari, Maria Jose Villar, Rakhi Kundu, Duc M. Nguyen, Leroy Versteeg, Ulrich Strych, Peter J. Hotez, Maria Elena Bottazzi, Jeroen Pollet, Kathryn M. Jones

Assuntos: Obter o texto integral

Enveloped virus-like particles as a platform for vaccine development Por Francisco Diaz-Mitoma

Assuntos: Obter o texto integral

Preclinical safety and immunogenicity evaluation of bioactive antimicrobial peptides Por Koh, Phay Chung

Assuntos: Obter o texto integral
Obter o texto integral

The Relationship between Immunogenicity and Reactogenicity of Seasonal Influenza Vaccine Using Different Delivery Methods Por Daniel J. Gromer, Brian D. Plikaytis, Michele P. McCullough, Sonia Tandon Wimalasena, Nadine Rouphael

Assuntos: Obter o texto integral

Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10–50 years old: Randomized, blinded, parallel controlled phase III clinical study Por Xiaoyuan Huang, Jing Liang, Lili Huang, Xuanxuan Nian, Wei Chen, Jiayou Zhang, Xiao Xu, Xuan Lin, Yue Wang, Jinrong Shi, Lanxin Jia, Qingliang Li, Qianxi Wang, Kai Duan, Xinguo Li, Yaqi Ji, Feixia Peng, Wei Zhang, Zhiqiang Xie, Yanxia Wang, Xiaoming Yang

Assuntos: Obter o texto integral

Immune response to the mumps component of the MMR vaccine in the routine of immunisation services in the Brazilian National Immunisation Program Por Eliane Matos dos Santos, Gloria Regina da Silva e Sá, Marilda Mendonça Siqueira, Reinaldo de Menezes Martins, Luiz Antonio Bastos Camacho, Vanessa dos Reis von Doellinger, Maria de Lourdes de Sousa Maia

Assuntos: Obter o texto integral

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews Por Rodrigo Luiz Carregaro, Alessandra N. C. P. Roscani, Augusto Cesar Sousa Raimundo, Larissa Ferreira, Tazio Vanni, Maria da Graça Salomão, Livia Fernandes Probst, Juliana Yukari K. Viscondi

Assuntos: Obter o texto integral

CIRCULATING ANTIBODIES TO ERYTHROPOIETIN ARE ASSOCIATED WITH LOWER EFFICACY OF RECOMBINANT EPOETIN TREATMENT IN PATIENTS UNDERGOING HAEMODIALYSIS Por V. D. Nazarov, S. V. Lapin, V. A. Dobronravov, K. A. Smirnov, D. A. Mayer, T. O. Muzhetskaya, A. A. Totolian

Assuntos: Obter o texto integral

An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators Por Nidhi Chauhan, Sukirti Tiwari, Tessy Iype, Utkarsh Jain

Assuntos: Obter o texto integral

A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine F... Por Joanne Langley, Elodie Pastural, Scott Halperin, Shelly McNeil, May ElSherif, Donna MacKinnon-Cameron, Lingyun Ye, Cécile Grange, Valérie Thibodeau, Jean-François Cailhier, Rejean Lapointe, Janet McElhaney, Luis Martin, Marilène Bolduc, Marie-Eve Laliberté-Gagné, Denis Leclerc, Pierre Savard

Assuntos: Obter o texto integral

Development and Validation of the ELISA Method for Anti-trastuzumab Antibodies Determination in Human Serum Por O. A. Eliseeva, M. A. Kolganova, I. E. Shokhin, S. P. Dementyev, A. M. Vlasov, A. A. Zamyatnin, N. S. Dubovik, A. Yu. Savchenko, N. V. Dozmorova, V. G. Luzhanin

Assuntos: Obter o texto integral

Evaluation of immunogenicity and safety of VARIVAX™ New Seed Process (NSP) in children Por Shelly D. Senders, Nickoya D. Bundick, Jianing Li, Carol Zecca, Frans A. Helmond

Assuntos: Obter o texto integral

Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine：a phase I clinical trial Por Zhi-Wei Wu, Qing-Liang Li, Hai-Song Zhou, Kai Duan, Zhao Gao, Xin-Jiang Zhang, Zhi-Jun Jiang, Zhi-Yong Hao, Fei Jin, Xuan Bai, Qi Li, Ge-Lin Xu, Yu-Liang Zhao, Xiao-Ming Yang

Assuntos: Obter o texto integral

Immunogenicity and safety of a new hexavalent rotavirus vaccine in Chinese infants: A randomized, double-blind, placebo-controlled phase 2 clinical trial Por Zhi-Wei Wu, Fei Jin, Qing-Liang Li, Jia-Mei Gao, Hai-Song Zhou, Kai Duan, Zhao Gao, Yan Liu, Zhi-Yong Hao, Wei Chen, Yue-Yue Liu, Ge-Lin Xu, Biao Yang, Ben Dong, Jiu-Wei Zhang, Yu-Liang Zhao, Xiao-Ming Yang

Assuntos: Obter o texto integral

Sleep and vaccine administration time as factors influencing vaccine immunogenicity Por Eun Seok Kim, Chi Eun Oh

Assuntos: Obter o texto integral

Immune correlates of protection of the four-segmented Rift Valley fever virus candidate vaccine in mice Por Chittappen K. Prajeeth, Isabel Zdora, Giulietta Saletti, Julia Friese, Thomas Gerlach, Lucas Wilken, Jana Beicht, Mareike Kubinski, Christina Puff, Wolfgang Baumgärtner, Jeroen Kortekaas, Paul J. Wichgers Schreur, Albert D.M.E. Osterhaus, Guus F. Rimmelzwaan

Assuntos: Obter o texto integral